Henlius Expands its Collaboration with Accord Healthcare to Launch Hansizhuang (serplulimab injection) in Europe and India for Various Indications
Shots:
- Under the terms of the agreement, Henlius will receive ~$44.5M as up front payment & is eligible for up to $45.5M in regulatory milestones along with $106M in commercial milestones plus double-digit royalties
- In return, Accord Healthcare (a subsidiary of Intas) received the exclusive development & commercialization rights for Hansizhuang across EU & India for various indication incl. ES-SCLC
- Hansizhuang is an anti-PD-1 mAb developed by Henlius for the treatment of multiple indications. It has been approved in China for 4 indications (MSI-H solid tumour, sqNSCLC, ES-SCLC & ESCC), received ODD by the US FDA & EMA (both for SCLC), expects EMA’s approval for SCLC by H1’24 & is under several clinical evaluations
Ref: PRNewswire | Image: Henlius
Related News:- Henlius Reports the NMPA Acceptance of NDA for Hansizhuang (serplulimab) to Treat Esophageal Squamous Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
